Association between the NEP rs701109 polymorphism and the clinical efficacy and safety of sacubitril/valsartan in Chinese patients with heart failure

[1]  Md. Habibur Rahman,et al.  Major implications of single nucleotide polymorphisms in human carboxylesterase 1 on substrate bioavailability. , 2022, Biotechnology & genetic engineering reviews.

[2]  A. Bayés‐Genís,et al.  Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review , 2021, Frontiers in Cardiovascular Medicine.

[3]  Nathalie Piñol-Domenech,et al.  Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta‐analysis , 2021, Pharmacology research & perspectives.

[4]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[5]  J. Schulz-Menger,et al.  Low‐fat hypocaloric diet reduces neprilysin in overweight and obese human subjects , 2021, ESC heart failure.

[6]  David K. Yang,et al.  Genome-wide functional screen of 3′UTR variants uncovers causal variants for human disease and evolution , 2021, Cell.

[7]  Huali Wang,et al.  The Association between Neprilysin gene polymorphisms and Alzheimer’s disease in Tibetan population , 2020, Brain and behavior.

[8]  Q. Shan,et al.  Beneficial Effects of Sacubitril/Valsartan at Low Doses in an Asian Real-World Heart Failure Population. , 2020, Journal of cardiovascular pharmacology.

[9]  E. Braunwald,et al.  Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. , 2020, JACC. Heart failure.

[10]  I. Diemberger,et al.  Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. , 2020, European journal of preventive cardiology.

[11]  P. Ponikowski,et al.  Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. , 2020, The New England journal of medicine.

[12]  Francesca N. Delling,et al.  Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association , 2020, Circulation.

[13]  Lucy Her,et al.  Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators , 2019, Drug Metabolism and Disposition.

[14]  C. Reid,et al.  Medical Therapies for Heart Failure With Preserved Ejection Fraction. , 2019, Hypertension.

[15]  Emily C. O'Brien,et al.  Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction , 2019, Journal of the American Heart Association.

[16]  C. Baigent,et al.  Chronic kidney disease, heart failure and neprilysin inhibition , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  A. Cohen-Solal,et al.  Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study , 2018, European journal of heart failure.

[18]  M. Hlatky,et al.  Innovation in Heart Failure Treatment: Life Expectancy, Disability, and Health Disparities. , 2018, JACC. Heart failure.

[19]  P. Neuvonen,et al.  Effects of Genetic Variants on Carboxylesterase 1 Gene Expression, and Clopidogrel Pharmacokinetics and Antiplatelet Effects , 2018, Basic & clinical pharmacology & toxicology.

[20]  Imad Hanna,et al.  Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition , 2018, Xenobiotica; the fate of foreign compounds in biological systems.

[21]  Xinwen Wang,et al.  A Comprehensive Functional Assessment of Carboxylesterase 1 Nonsynonymous Polymorphisms , 2017, Drug Metabolism and Disposition.

[22]  H. Rasmussen,et al.  The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects , 2017, British journal of clinical pharmacology.

[23]  Shannon M. Dunlay,et al.  Epidemiology of heart failure with preserved ejection fraction , 2017, Nature Reviews Cardiology.

[24]  S. Solomon,et al.  Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF , 2017, European heart journal.

[25]  Xinwen Wang,et al.  Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. , 2016, Biochemical pharmacology.

[26]  G. Tiscia,et al.  Pharmacogenetics of dabigatran etexilate interindividual variability. , 2016, Thrombosis research.

[27]  Shiqi Peng,et al.  Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis , 2016, European Journal of Clinical Pharmacology.

[28]  A. Andriulli,et al.  Genetic variants of membrane metallopeptidase genes in inflammatory bowel diseases. , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[29]  L. Williams,et al.  Association of Genetic Variation with Gene Expression and Protein Abundance within the Natriuretic Peptide Pathway , 2013, Journal of Cardiovascular Translational Research.

[30]  S. Yusuf,et al.  Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding , 2013, Circulation.

[31]  L. Rohde,et al.  Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate , 2012, The Pharmacogenomics Journal.

[32]  J. Gádoros,et al.  Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD , 2009, Neuropharmacology.

[33]  J. Markowitz,et al.  Activation of the Antiviral Prodrug Oseltamivir Is Impaired by Two Newly Identified Carboxylesterase 1 Variants , 2009, Drug Metabolism and Disposition.

[34]  Julie A. Johnson,et al.  Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. , 2008, American journal of human genetics.

[35]  H. Soininen,et al.  Polymorphisms in neprilysin gene affect the risk of Alzheimer’s disease in Finnish patients , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[36]  M. Yamada,et al.  Association of neprilysin polymorphism with cerebral amyloid angiopathy , 2003, Journal of neurology, neurosurgery, and psychiatry.